Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.
Video Library —July 18, 2018
Categories:
Interview with the InnovatorsThoracic Oncologist, Dana-Farber Cancer Institute,
Associate Professor of Medicine, Harvard Medical School,
Boston, MA
Associate Professor of Medicine, Harvard Medical School,
Boston, MA
Molecular Pathologist and Co-Director
Molecular Diagnostics and Clinical Genomics Laboratories, University of Chicago
Chicago, IL
Molecular Diagnostics and Clinical Genomics Laboratories, University of Chicago
Chicago, IL
Last modified: August 10, 2023